Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

GE HealthCare notches FDA clearance of Allia IGS Pulse platform

Jocelyn Aspa Jocelyn Aspa, The Market Online
0 Comments| October 16, 2023

{{labelSign}}  Favorites
{{errorMessage}}

  • GE HealthCare (NASDAQ:GEHC) has received U.S. Food and Drug Administration (FDA) clearance for its Allia IGS Pulse Platform
  • Allia IGS is an image-guided system (IGS) that offers a new imaging chain to provide imaging at the right dose for impact in cardiology interventions
  • The system includes the first monopolar X-ray tube used for interventional procedures
  • Shares of GE HealthCare are up 0.19 per cent to US$67.25 as of 11:15 am ET

GE HealthCare (NASDAQ:GEHC) has notched US Food and Drug Administration (FDA) clearance for its Allia IGS Pulse Platform. The platform is an image-guided system (IGS) that offers new imaging at the right dose for impacting cardiology interventions.

In a newsrelease, the company stated the Allia IGS Pulse platform is intended to improve workflow for diagnosing and treating cardiovascular diseases in interventional technology.

“Interventional cardiology procedures require exceptional image quality,” Arnaud Marie, general manager of Interventional for GE HealthCare, said in a statement. “I’m excited by the addition of Allia IGS Pulse to our interventional offerings because it addresses the very things clinicians continue to tell us present challenges in their day-to-day practice.”

The company said the platform also features the first monopolar X-ray tube to capture images for interventional procedures.

Notably, the tube optimizes the operating environment during a procedure and assists clinicians with a better understanding of coronary artery anatomy.

Over the course of 2023, the Allia IGS Pulse platform has been in pilot operations at Clinique Pasteur Toulouse in France.

The company stated that Allia IGS Pulse will be showcased for the first time at the Transcatheter Cardiovascular Therapeutics 2023 conference.

GE HealthCare is a global medical technology, pharmaceutical diagnostics, and digital solutions company. It is focused on providing integrated solutions, services, and data analytics.

Shares of GE HealthCare are up 0.19 per cent to US$67.25 as of 11:15 am ET.

Join the discussion: Find out what everybody’s saying about this stock on the GE Healthcare Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.



{{labelSign}}  Favorites
{{errorMessage}}